摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(1-piperidinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide | 179626-18-7

中文名称
——
中文别名
——
英文名称
2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(1-piperidinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide
英文别名
8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methyl-4-piperidinoquinoline;2-amino-N-[2,4-dichloro-3-[(2-methyl-4-piperidin-1-ylquinolin-8-yl)oxymethyl]phenyl]-N-methylacetamide
2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(1-piperidinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide化学式
CAS
179626-18-7
化学式
C25H28Cl2N4O2
mdl
——
分子量
487.429
InChiKey
OQICGORVIOAESP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    33
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    71.7
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (E)-4-(2-oxopyrrolidin-1-yl)cinnamic acid2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(1-piperidinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide 在 1-(3-dimethylaminopropyl)-3-ethoxycarbodiimide hydrochloride 、 1-羟基苯并三唑 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 3.0h, 以80.2%的产率得到(2E)-N-{2-[2,4-dichloro(methyl)-3-({[2-methyl-4-(1-piperidinyl)-8-quinolinyl]oxy}methyl)anilino]-2-oxoethyl}-3-[4-(2-oxo-1-pyrrolidinyl)phenyl]-2-propenamide
    参考文献:
    名称:
    A New Class of Nonpeptide Bradykinin B2 Receptor Ligand, Incorporating a 4-Aminoquinoline Framework. Identification of a Key Pharmacophore To Determine Species Difference and Agonist/Antagonist Profile
    摘要:
    Introduction of various aliphatic amino groups at the 4-position of the quinoline moiety of our nonpeptide bradykinin (BK) B-2 receptor antagonists afforded highly potent ligands for human B-2 receptor with various affinities for guinea pig B-2 receptor, indicating remarkable species difference. A representative 4-dimethyamino derivative 40a exhibited subnanomolar and nanomolar binding affinities for human and guinea pig B-2 receptors, respectively, and significantly inhibited BK-induced bronchoconstriction in guinea pigs at 10 mug/kg by intravenous administration. Further chemical modification led us to discover unique partial agonists for the human B-2 receptor that increase inositol phosphates (IPs) production by themselves in Chinese hamster ovary (CHO) cells expressing the cloned human B-2 receptor. Although their potency and efficacy were much lower than those of BK, we identified them as screening leads for nonpeptide B-2 agonists. In these studies it was revealed the 4-substituent of the quinoline moiety is the key pharmacophore to determine species difference and agonist/antagonist profiles.
    DOI:
    10.1021/jm030326t
  • 作为产物:
    参考文献:
    名称:
    A New Class of Nonpeptide Bradykinin B2 Receptor Ligand, Incorporating a 4-Aminoquinoline Framework. Identification of a Key Pharmacophore To Determine Species Difference and Agonist/Antagonist Profile
    摘要:
    Introduction of various aliphatic amino groups at the 4-position of the quinoline moiety of our nonpeptide bradykinin (BK) B-2 receptor antagonists afforded highly potent ligands for human B-2 receptor with various affinities for guinea pig B-2 receptor, indicating remarkable species difference. A representative 4-dimethyamino derivative 40a exhibited subnanomolar and nanomolar binding affinities for human and guinea pig B-2 receptors, respectively, and significantly inhibited BK-induced bronchoconstriction in guinea pigs at 10 mug/kg by intravenous administration. Further chemical modification led us to discover unique partial agonists for the human B-2 receptor that increase inositol phosphates (IPs) production by themselves in Chinese hamster ovary (CHO) cells expressing the cloned human B-2 receptor. Although their potency and efficacy were much lower than those of BK, we identified them as screening leads for nonpeptide B-2 agonists. In these studies it was revealed the 4-substituent of the quinoline moiety is the key pharmacophore to determine species difference and agonist/antagonist profiles.
    DOI:
    10.1021/jm030326t
点击查看最新优质反应信息

文献信息

  • PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP0807105B1
    公开(公告)日:2004-06-16
  • US5994368A
    申请人:——
    公开号:US5994368A
    公开(公告)日:1999-11-30
  • A New Class of Nonpeptide Bradykinin B<sub>2</sub> Receptor Ligand, Incorporating a 4-Aminoquinoline Framework. Identification of a Key Pharmacophore To Determine Species Difference and Agonist/Antagonist Profile
    作者:Yuki Sawada、Hiroshi Kayakiri、Yoshito Abe、Tsuyoshi Mizutani、Noriaki Inamura、Masayuki Asano、Ichiro Aramori、Chie Hatori、Teruo Oku、Hirokazu Tanaka
    DOI:10.1021/jm030326t
    日期:2004.5.1
    Introduction of various aliphatic amino groups at the 4-position of the quinoline moiety of our nonpeptide bradykinin (BK) B-2 receptor antagonists afforded highly potent ligands for human B-2 receptor with various affinities for guinea pig B-2 receptor, indicating remarkable species difference. A representative 4-dimethyamino derivative 40a exhibited subnanomolar and nanomolar binding affinities for human and guinea pig B-2 receptors, respectively, and significantly inhibited BK-induced bronchoconstriction in guinea pigs at 10 mug/kg by intravenous administration. Further chemical modification led us to discover unique partial agonists for the human B-2 receptor that increase inositol phosphates (IPs) production by themselves in Chinese hamster ovary (CHO) cells expressing the cloned human B-2 receptor. Although their potency and efficacy were much lower than those of BK, we identified them as screening leads for nonpeptide B-2 agonists. In these studies it was revealed the 4-substituent of the quinoline moiety is the key pharmacophore to determine species difference and agonist/antagonist profiles.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物